PVCT PROVECTUS BIOPHARMACEUTICALS, INC.
Pharmaceutical Preparations · OTC · SEC CIK 315545 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-45.5%
TTM net income YoY-14.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-30.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,575.3%
Net margin-1,615.8%
FCF margin—
EBITDA margin-1,574.8%
Returns
ROE—
ROA-637.5%
ROIC (approx.)—
Asset turnover0.39x
Leverage & solvency
Liabilities / assets1,003.6%
Debt / equity—
Current ratio0.08x
Interest coverage-991.90x
Cash quality & payout
Operating cash flow / net income0.61x
Accruals ratio-247.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $57,480 | $278,628 | $14,332 |
| R&D expense | $240,320 | $131,130 | $333,334 | $268,428 | $345,861 | $880,835 | $402,704 | $556,678 |
| SG&A expense | $971,045 | $807,548 | $914,569 | $852,061 | $929,746 | $977,373 | $973,865 | $1.79M |
| Operating income | -$1.21M | -$938,678 | -$1.25M | -$1.12M | -$1.28M | -$1.80M | -$1.10M | -$2.33M |
| Interest expense | $62,345 | $50,319 | $53,046 | -$157,698 | $48,022 | $51,353 | $63,661 | — |
| Net income | -$1.27M | -$982,566 | -$1.29M | -$1.17M | -$1.31M | -$1.81M | -$1.14M | -$2.37M |
| EBITDA | -$1.21M | -$938,212 | -$1.25M | -$1.12M | -$1.28M | -$1.80M | -$1.10M | -$2.33M |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 420.28M | 420.28M | 420.28M | — | 420.28M | 420.28M | 420.28M | — |
| Banking | ||||||||
| Net interest income | — | — | — | -$47,323 | -$48,022 | -$51,353 | -$63,661 | -$62,322 |
| Balance sheet | ||||||||
| Cash & equivalents | $180,733 | $1.16M | $223,883 | $251,291 | $72,479 | $385,929 | $390,435 | $307,442 |
| Current assets | $375,197 | $1.37M | $460,385 | $567,874 | $277,988 | $568,320 | $649,469 | $976,772 |
| PP&E, net | $1,603 | $2,068 | $2,534 | $3,000 | $3,465 | $3,931 | $4,396 | $4,863 |
| Total assets | $467,087 | $1.47M | $577,580 | $697,502 | $419,904 | $722,384 | $666,257 | $1.01M |
| Current liabilities | $7.11M | $7.71M | $7.24M | $6.90M | $6.47M | $6.49M | $5.74M | $6.98M |
| Total liabilities | $7.15M | $7.76M | $7.31M | $7.00M | $6.59M | $6.60M | $5.74M | $6.98M |
| Shareholders' equity | -$6.66M | -$6.28M | -$6.72M | -$6.30M | -$6.15M | -$5.87M | -$5.10M | -$5.96M |
| Shares outstanding | 420.28M | 420.28M | 420.28M | 420.28M | 420.28M | 420.28M | — | 420.28M |
| Cash flow statement | ||||||||
| Operating cash flow | -$859,595 | -$358,249 | -$357,565 | -$869,553 | -$839,867 | -$523,127 | -$1.09M | -$912,008 |
| Financing cash flow | -$116,755 | $1.29M | $329,872 | $1.05M | $495,903 | $469,759 | $1.07M | $788,419 |
| Depreciation & amortization | $465 | $466 | $466 | $465 | $466 | $465 | $467 | $466 |
| Stock-based compensation | $309,306 | $305,944 | $306,051 | $287,601 | $312,775 | $322,070 | $315,100 | $331,371 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.